DoseMe today announced former Head of Cognitive Health and Life Sciences at IBM Research – Australia, Dr Priscilla Rogers, will join the DoseMe Advisor Board.
“I am thrilled to welcome Priscilla to our Advisory Board. Her vast experience in emerging market and healthcare technology solutions will be invaluable as we continue to rapidly scale our fast-growing business,” said Charles Cornish, Chief Executive Officer, DoseMe.
Priscilla is currently Vice President at Wintermute Biomedical, a US biopharmaceutical company developing a next-generation antibiotic to combat antimicrobial resistance. Prior to this, she was leading the Cognitive Health & Life Sciences portfolio at IBM Research – Australia, focusing on the research and development of artificial intelligence solutions in healthcare.
Priscilla commented: “It was clear from the first time I met Charles that we share the same vision to transform healthcare from the “one-size-fits-all” approach towards personalised, data-driven decision making. The rapid advancements in artificial intelligence show that personalised medicine is not something that needs to remain futuristic. DoseMe is evidence of that.
“A large part of the recipe for success is ensuring you have the right team. DoseMe has the foundations to make a real difference in precision dosing globally. I’m excited to be a part of that and help with DoseMe’s continued success,” she said.
Priscilla joins DoseMe Advisor Board member’s Dr Simon Kos, Global Chief Medical Officer, Worldwide Health Microsoft, Dr Jeremy Friese Director of pharmacogenomics company OneOme and Dr Syed Tabish R. Zaidi, Senior Lecturer, University of Tasmania.
To read more about Priscilla and the DoseMe Advisor Board Members, please visit our team page.